Supriya Lifescience has announced its unaudited financial results for the first quarter of FY27, ending June 30, 2026. The company reported a robust 30.8% year-over-year revenue growth to Rs 189.75 crore, driven by strong performance in its core business and global market presence. However, EBITDA saw a decline to Rs 47.46 crore from Rs 51.70 crore in Q1 FY26, impacting the Profit After Tax (PAT) to Rs 24.04 crore, down from Rs 34.79 crore.
Supriya Lifescience Reports Q1 FY27 Financial Highlights
Revenue Growth Driven by Global Presence
Supriya Lifescience Ltd. has reported its unaudited financial results for the quarter ended June 30, 2026. The company announced a significant 30.8% year-over-year increase in revenue, reaching Rs 189.75 crore for Q1 FY27, compared to Rs 145.07 crore in the same period last year. This growth is attributed to continued momentum in its core business and a diversified presence across global markets, with exports contributing 81% of the revenue.
Profitability Trends
Despite the substantial revenue jump, EBITDA for Q1 FY27 stood at Rs 47.46 crore, marking a decrease from Rs 51.70 crore in Q1 FY26. Consequently, the EBITDA margin narrowed to 25.0% from 35.6%. The Profit After Tax (PAT) also saw a decline, reporting Rs 24.04 crore for Q1 FY27, down from Rs 34.79 crore in Q1 FY26. This resulted in a lower PAT Margin of 12.7% compared to 24.0% in the prior year.
Segmental Performance and Future Outlook
The Anesthetic segment remained the largest therapeutic contributor, accounting for 48% of revenue in Q1 FY27, while Vitamins contributed 17%. The company is focusing on expanding its product portfolio and strengthening manufacturing and R&D capabilities. Plans are underway for approximately two new product launches each in the Anesthetic and ADHD segments in FY27, aiming to deepen the product pipeline and support future growth. The Ambernath facility has also commissioned its finished dosage manufacturing capabilities, covering multiple dosage forms.
Dr. Satish Wagh, Executive Chairman and Whole-Time Director, commented, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets.”
Source: BSE
